SCHEMBL15035740

SCHEMBL15035740

Cc1scnc1-c1cc2cnc(Nc3ccc(C4CCNC4)cc3)nc2n(Cc2cccc(S(=O)(=O)c3ccccc3)c2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK2 O43353 3/20 0.43
NOD2 Q9HC29 3/20 0.43
ACVR1 Q04771 2/20 0.43
JAK2 O60674 3/20 0.42
BRD4 O60885 3/20 0.42
JAK1 P23458 1/20 0.42
BRD2 P25440 1/20 0.42
JAK3 P52333 1/20 0.42
BRD3 Q15059 1/20 0.42
BRDT Q58F21 1/20 0.42
EGFR P00533 1/20 0.39
FGFR1 P11362 1/20 0.39
USP2 O75604 3/20 0.38
TSHR P16473 2/20 0.38
CASP1 P29466 2/20 0.38
CASP7 P55210 2/20 0.38
HIF1A Q16665 2/20 0.38
LMNA P02545 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041826 0.81 JAK2 (0.46) JAK2BRD4JAK1BRD2JAK3
SCHEMBL15034932 0.80 PAK4 (0.42) JAK2BRD4JAK1BRD2JAK3
SCHEMBL15035689 0.80 RIPK2 (0.39) RIPK2NOD2ACVR1JAK2BRD4
SCHEMBL15035037 0.79 PAK4 (0.38) JAK2BRD4JAK1BRD2JAK3
SCHEMBL15035652 0.79 EGFR (0.36) RIPK2NOD2ACVR1JAK2BRD4
SCHEMBL15035902 0.79 JAK2 (0.37) JAK2BRD4JAK1BRD2JAK3
SCHEMBL15034821 0.79 PAK4 (0.39) JAK2BRD4JAK1BRD2JAK3
SCHEMBL15035921 0.78 PLK2 (0.38) RIPK2NOD2ACVR1JAK2BRD4
SCHEMBL15034844 0.77 FGFR1 (0.35) JAK2BRD4JAK1BRD2JAK3
SCHEMBL15237005 0.77 JAK2 (0.36) JAK2BRD4JAK1BRD2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-26 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252967-A1 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK6 RIPK2 1162/4885NOD2 4034/4885ACVR1 4860/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 RIPK2 971/4885NOD2 4628/4885ACVR1 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.